 |
Adam Bonislawski is the editor of GenomeWeb's ProteoMonitor. He covers proteomics and life science mass spectrometry. E-mail Adam Bonislawski and follow his GenomeWeb Twitter account at @ProteoMonitor. |
Lund Team Looks to Commercialize Immunoaffinity-MS Method for Tumor Grading, Discovery Proteomics
May 04, 2012
Lund Team Looks to Commercialize Immunoaffinity-MS Method for Tumor Grading, Discovery Proteomics
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Lund Scientists Develop Immunoaffinity-MS Workflow for Discovery Proteomics
August 12, 2011 / ProteoMonitor - GenomeWeb Feature: The Unsteady March of Cancer Protein Biomarkers into the Clinic
May 10, 2013 / ProteoMonitor - Theranostics Health to Launch HER Signaling Assay, Marking Firm's First Commercial Test Release
May 3, 2013 / ProteoMonitor - Genomics in the Journals
April 4, 2013 / GenomeWeb Daily News - Caprion Leading $21M Clinical Biomarker and Personalized Medicine Development Project
February 22, 2013 / ProteoMonitor